|
Purpose: in vitro and in vivo antibacterial test observation imipenem, polymyxin B, rifamycin sodium minocycline and other factors antimicrobial combination of pan-resistant Bowman of Acinetobacter antibacterial activity and efficacy, investigate the treatment of pan-resistant Acinetobacter baumannii. Method: First application doubling dilution method and the checkerboard method imipenem, polymyxin B, rifamycin sodium, minocycline doxycycline and other antibacterial drugs were determined for 20 clinical isolates of pan-resistant Acinetobacter bacilli, a single agent in vitro and the United antibacterial activity, and to explore possible joint way. Then create a mouse pan-resistant Acinetobacter baumannii pneumonia model agranulocytosis Finally, treatment of infected mice with a combination of a variety of antibiotics, to observe the survival time of the mice in each group, and the degree of lung tissue inflammation and bacterial colony counts to determine The combination of the Strains of Acinetobacter efficacy. Joint: In vitro susceptibility testing results: be detected 20 resistant Acinetobacter imipenem and piperacillin synergistic effect of the combination of 30%; imipenem and minocycline combination therapy The synergistic effect of 55%; 65% of the synergies of the combination of imipenem rifamycin sodium; imipenem and polymyxin B combination synergies of up to 60%. This test was successfully constructed agranulocytosis mouse pan-resistant Acinetobacter baumannii pneumonia model, this animal model in vivo test results showed that: 1, polymyxin B 24h and 48h of pan-resistant Bowman Acinetobacter bactericidal effect (≥ 3 △ lg CFU · mL-1), is the only the radiolabeling drug treatment is effective antimicrobial drugs (P lt; 0.05); 2, in combination, the combination of imipenem and polymyxin B in 24h and 48h, respectively, showed bactericidal effect (≥ 3 △ lg CFU · mL-1) and synergies; Yaanpeian and rifamycin sodium, imipenem and minocycline combination of imipenem have a bactericidal effect (≥ 3 △ lg CFU · mL-1) and synergy (48h) and of piperacillin tazobactam combination therapy in 48h. The combination of imipenem and sulbactam independent role. Conclusion: imipenem and piperacillin tazobactam, minocycline, rifamycin sodium, polymyxin B combination, in vitro synergy lowest rate of up to 30%. In mice Acinetobacter baumannii pneumonia model, imipenem and piperacillin tazobactam, minocycline, rifamycin sodium, polymyxin B combination showed synergistic ; combination of imipenem and sulbactam independent role.
|